The Pharma Data
SEPTEMBER 15, 2020
Find out solutions to mitigate the impact from clinical supply chain risk and discover how to improve dynamic drug supply forecasting strategies. Enrolling study subjects, setting up patient randomization and managing drug supply are critical to the success of a clinical trial.
PPD
FEBRUARY 12, 2025
Unlocking new levels of value with expanded offerings We are launching more dynamic and integrated service offerings that leverage the very latest automation and integrations to accelerate your unique drug development journey in new and different ways.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Conversations in Drug Development Trends
NOVEMBER 12, 2024
While clinical supply is essential to any successful trial, autologous cell therapy trials occupy the far end of the spectrum regarding risk tolerance. Delivering this cellular drug product into the patient’s body, followed by intensive medical oversight.
The Pharma Data
MAY 26, 2023
The expansion forms part of Catalent’s ongoing global strategy to increase its ability to handle, store and manage advanced therapies for clinical supply, and follows investments at its facilities in Philadelphia, Singapore, and Shanghai, China, in specialized, ultra-low temperature storage capabilities. With sites in the U.S.,
PPD
SEPTEMBER 6, 2023
Approaches to outsourcing clinical trials have changed significantly in recent years. Mixing of service models — a strategy that drug developers are leveraging now more than ever — can bring life-changing therapies to market faster. Most often done using the vendor’s systems and standard operating procedures (SOP).
The Pharma Data
SEPTEMBER 14, 2020
Supply chain uncertainty is a challenge every clinical supply chain manager wrestles with – stemming from increasing product demand and quality, the growing complexity of clinical trial designs and a lack of visibility in the supply chain. Maintaining optimization during clinical trial design.
Drug Target Review
SEPTEMBER 10, 2024
The current landscape of protein drug development is characterised by accelerated timelines where new drugs are approved in months rather than years. Hence, in many cases an earlier IND may be prevented by the timely provision of representative Drug Substance (DS) to execute such toxicology studies.
Expert insights. Personalized for you.
52 
Let's personalize your content